Cancer - IDEAYA Biosciences, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05987332

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)

Drug

IDE196

Condition

Uveal melanoma